Top

Published in:

01-04-2008 | ORIGINAL COMMUNICATION

Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b

Authors: Prof. C. Polman, MD, PhD, L. Kappos, M. S. Freedman, G. Edan, H.-P. Hartung, D. H. Miller, X. Montalbán, F. Barkhof, K. Selmaj, B. M. J. Uitdehaag, S. Dahms, L. Bauer, C. Pohl*, R. Sandbrink*, for the BENEFIT investigators**

Published in: Journal of Neurology | Issue 4/2008

Title: Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b
Authors: Prof. C. Polman, MD, PhD
L. Kappos
M. S. Freedman
G. Edan
H.-P. Hartung
D. H. Miller
X. Montalbán
F. Barkhof
K. Selmaj
B. M. J. Uitdehaag
S. Dahms
L. Bauer
C. Pohl*
R. Sandbrink*
for the BENEFIT investigators**
Publication date: 01-04-2008
Publisher: Steinkopff-Verlag
Published in: Journal of Neurology / Issue 4/2008
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-007-0733-2

At a glance: The STEP trials

Springer Medicine

Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b

At a glance: The STEP trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 4/2008

Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis

Spinocerebellar ataxia type 4 and 16q22.1-linked Japanese ataxia are not allelic

“Pseudodominant inheritance” of ataxia with ocular apraxia type 2 (AOA2)

Volumetric MRI and cognitive measures in Alzheimer disease

Josef Gerstmann (1887–1969)

18F-FDG PET in neurodegenerative Langerhans cell histiocytosis